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Abstract
Chagas disease caused by Trypanosoma cruzi is a complex disease that is endemic and an important problem in public health
in Latin America. The T. cruzi parasite is classified into six discrete taxonomic units (DTUs) based on the recently proposed
nomenclature (TcI, TcII, TcIII, TcIV, TcV and TcVI). The discovery of genetic variability within TcI showed the presence of five
genotypes (Ia, Ib, Ic, Id and Ie) related to the transmission cycle of Chagas disease. In Colombia, TcI is more prevalent but TcII
has also been reported, as has mixed infection by both TcI and TcII in the same Chagasic patient. The objectives of this study
were to determine the T. cruzi DTUs that are circulating in Colombian chronic Chagasic patients and to obtain more
information about the molecular epidemiology of Chagas disease in Colombia. We also assessed the presence of
electrocardiographic, radiologic and echocardiographic abnormalities with the purpose of correlating T. cruzi genetic
variability and cardiac disease. Molecular characterization was performed in Colombian adult chronic Chagasic patients based
on the intergenic region of the mini-exon gene, the 24Sa and 18S regions of rDNA and the variable region of satellite DNA,
whereby the presence of T.cruzi I, II, III and IV was detected. In our population, mixed infections also occurred, with TcI-TcII,
TcI-TcIII and TcI-TcIV, as well as the existence of the TcI genotypes showing the presence of genotypes Ia and Id. Patients
infected with TcI demonstrated a higher prevalence of cardiac alterations than those infected with TcII. These results
corroborate the predominance of TcI in Colombia and show the first report of TcIII and TcIV in Colombian Chagasic patients.
Findings also indicate that Chagas cardiomyopathy manifestations are more correlated with TcI than with TcII in Colombia.
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Introduction
Chagas disease caused by the parasite Trypanosoma cruzi is a
complex zoonosis that is widely distributed throughout the
American continent. The infection can be acquired by triatomine
faeces, blood transfusion, oral and congenital transmission and by
laboratory accidents. Chagas disease represents an important
public health problem, with estimates by the Pan American Health
Organization in 2005 of at least 7.7 million people having T. cruzi
infection and other 110 million being at risk [1]. Also, immigration
of infected people from endemic countries is now making Chagas
disease a relevant health issue in other regions, including Europe
and the United States [2]. Chagas disease comprises two stages
where the acute phase occurs about one week after initial infection
and about 30–40% of the infected patients develop the chronic
phase of the disease, when the cardiomyopathy is the most
frequent and severe clinical manifestation. [2]
The T. cruzi parasite comprises a heterogeneous population that
displays clonal propagation due to the different cycles of
transmission, and the possibility of recombination exchange that
can be found in nature and has been previously reported in vitro
[3,4,5]. Recently a new nomenclature for T. cruzi has been
adopted and includes six Discrete Taxonomic Units (DTUs)
named as T. cruzi I (TcI), T. cruzi II (TcII), T. cruzi III (TcIII), T.
cruzi IV (TcIV), T. cruzi V (TcV) and T. cruzi VI (TcVI) based on
different molecular markers and biological features [6]. Recent
studies based on mini-exon gene sequences have shown polymor-
phism on this region reporting four genotypes within TcI
Colombian isolates, these genotypes have also been reported in
other regions of South America where five TcI genotypes have
been detected [7]. Also different molecular markers including a 48
set of microsatellite loci have shown the great diversity in TcI
[8,9,10,11]. Primers designed based on the sequences of TcI
Colombian isolates confirmed the existence of three genotypes (Ia,
Ib and Id) and a new genotype found in the southern cone
countries named as TcIe [7,12], also the use of Internal
Transcribed Spacers 1 and 2 clustered the genotypes Ia, Ib and
Id as being related to transmission cycles of Chagas disease [13].
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reporting homogeneous (TcII) and heterogeneous groups consid-
ered hybrids due to recombination events (TcIII-TcVI)
[3,4,5,14,15,16,17]. Hybrids are considered within T. cruzi
showing TcV and TcVI as products of recombination of TcII
and TcIII and TcIII/TcIV as potential products of recombination
of TcI and TcII [5,16], although this last statement is still
controversial.
The molecular epidemiology of T. cruzi may have important
implications on the disease features. However, few correlations
have been relating T. cruzi genetic variability and the disease
outcome, showing TcI more related to patients with cardiomyop-
athy in Colombia and Venezuela and TcII-TcVI more related to
patients with digestive syndrome (megaesophagus/megacolon)
[2,18]. In Colombia, TcI is predominant in patients, insect vectors
and reservoirs, but TcII has also been reported. The first
description of nine chronic Chagasic patients infected with TcII
was reported by Zafra et al., 2008 [19] and also mixed infection
with TcI and TcII in the same patient was reported [20]. The
direct detection of T. cruzi DTUs in the blood of chronic Chagasic
patients was established by amplification of the 24Sa rDNA
divergent domain and the use of mitochondrial house-keeping
genes [19]. In this study, molecular characterisation of T. cruzi
DTUs showed that most of the patients were infected with TcI and
some patients were found infected with TcII (9.9%). Recently, a
new approach of T. cruzi DTUs detection in chronic Chagasic
patients was developed showing that TcI was the predominant
DTU and TcII was also detected reporting that the genetic
characteristics of the TcII parasites found in Colombia were
similar to those TcII found in Bolivia and Chile [21].
The objective of our study was to characterise and determine T.
cruzi DTUs in chronic Chagasic patients from Colombia and to
correlate the molecular variability of the parasite with the presence
or absence of cardiac disease manifestations exhibited by the
patients.
Methods
Ethics statement, sample collection and DNA isolation
A total of 240 seropositive chronic Chagasic patients were
included in the study, as part of the Colombian population
recruited for the BENEFIT trial (BENznidazol Evaluation For
Interrupting Trypanosomiasis project (BENEFIT). Samples were
taken as part of the main BENEFIT trial that has recruited to date
2150 patients from Argentina, Bolivia, Brazil, El Salvador and
Colombia. Written and oral consent was obtained in all patients
included as part of the BENEFIT trial, the study is approved by all
local and national IRBs. Furthermore the study is approved by the
Ethics Research Committe of the WHO as one of the funding
agencies of the BENEFIT trial, [22]. All patients regardless of a
positive or negative baseline PCR are being followed as part of the
main trial which outcome is a composite of clinical events
referenced in the text [22]. Following the inclusion and exclusion
criteria for the BENEFIT study, all patients had cardiomyopathy,
as defined by the pre-established ECG or Echo abnormalities.
Twenty serologically negative control patients from non-endemic
regions were also included. A 10-mL blood sample was collected
from all patients and control subjects. Blood samples were mixed
with an equal volume of 6 M guanidine HCl/0.2 M EDTA
solution immediately after sample collection. The samples were
immersed in boiling water for 15 min. After cooling, two 200-mL
aliquots were taken from each patient blood lysate and successive
phenol-chloroform extractions were performed on this material as
previously reported [23]. The DNA was then stored at 220uC.
The DNA purity and concentrations were determined using an
Eppendorf Biophotometer 6131 at 260/280 nm.
T. cruzi molecular detection and molecular
characterisation
Molecular detection was performed amplifying the variable
region of kinetoplast DNA (kDNA) using primers 121 (59AAA-
TAATGTACGGGKGAGATGCATGA39) and 122 (59GGTTC-
GATTGGGGTTGGTGTAATATA 39), and tandem repeat
satellite region from T. cruzi using primers cruzi1 (59ASTCGGCT-
GATCGTTTTCGA39) and cruzi2 (59AATTCCTCCAAGCA-
GCGGATA 39). Molecular characterisation of T. cruzi was carried
out using five molecular markers that have been previously
evaluated. The intergenic region of the non-transcribed mini-exon
gene using primers TCC (59CCC CCC TCC CAG GCC ACA
CTG 39), TC1 (59GTG TCC GCC ACC TCC TTCGGG CC 39)
and TC2 (59CCT GCA GGC ACA CGT GTG TGT G 39); all
mini-exon gene PCR assays were performed using two primers
instead of a multiplex PCR assay to determine the presence of
mixed infections. Thus, PCR was employed using TCC-TC1 and
TCC-TC2 primers. The variable domain D7 of the rDNA 24Sa
subunit using primers D71 (59AAG GTG CGT CGA CAG TGT
GG 39) and D72 (59 TTT TCA GAA TGG CCG AAC AGT 39),
the primers V1 (59CAA GCG GCT GGG TGG TTA TTC CA
39) and V2 (59TTG AGG GAA GGC ATG ACA CAT GT 39)
amplifying the 18S rRNA ribosomal sequence of T. cruzi and the
repetitive region of satellite DNA using primers Diaz8 (59 TGT
TCA CAC ACT GGA CAC CAA 39) and TcSat4 (59GCA GCC
GCT CGA AAA CTA TCC 39) by conventional PCR and qPCR
using primers TcZ1 (5-9CGAGCTCTTGCCCACACGGGTG-
CT3)9 and SatRv (59TTCAGRGTTGTTTGGTGTCCAGT-
G39) from T. cruzi (Figure 1). For all molecular markers, the
amplification reactions were performed in a total volume of 21 mL.
This reaction consisted of 1X of Taq polymerase amplification
buffer (100 mM Tris-HCl, pH 8.3; Invitrogen), 100 mM dNTPs
solution, 50 mM MgCl2 solution, 5 Units/mL of Taq polymerase
platinum (Invitrogen), 50 pM of each primer, 3 mL of DNA
template and water to give a final total volume of 21 mL.
Amplification cycles were applied in an automatic thermocycler
(BIORAD iCycler) as previously reported [24,25,26]. The real-
time PCR assay was performed using 2X Supermix SYBR green
iQ (100 mM KCl, 40 mM Tris-HCI, pH 8.4, 0.4 mM dNTP,
Author Summary
Trypanosoma cruzi the aetiological agent of Chagas
disease infects over 8 million people in Latin America.
Currently, six genetic groups or DTUs have been identified
in this highly genetic and diverse parasite. Many authors
have considered that disease installation is induced by this
genetic variability in T. cruzi but few comparisons have
been made to make an approach of this premise. We
performed an analysis including 240 chronic ascertained
Chagasic patients evaluating cardiac alterations in electro-
cardiogram, radiology and echocardiogram. Also, we
developed molecular characterisation on samples from
these patients showing that in Colombia T.cruzi I is the
predominant but others such as TcII, TcIII and TcIV can be
found in low proportions as mixed infections TcI/TcII-TcIV.
We conclude that TcI is more related to cardiomyopathy
than TcII and we show the first report of TcIII and IV in
chronic Chagasic patients from Colombia. These results
will help to elucidate the molecular epidemiology of T.
cruzi in this country.
Heart Alterations and T. cruzi Genetic Variability
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20 nM fluorescein); 50 pM of TcZ1 and SatRv primers and 3 mL
of DNA, the thermal profile and acquisicion of fluorescence was
used as previously reported [27]. Molecular identification of
genotypes in TcI was accomplished using primers 1-A (59TGT
GTG TGT ATG TAT GTG TGT GTG 39), 1-B (59 CGG AGC
GGT GTG TGC AG 39) for the identification of genotype Ia with
an amplification product of 288 bp; 2-A (59TGT GTG TGT
GTA TGT ATG TAT GCT 39), 2-B (59GGA ACA CAC GCG
ACT AAT-39) for the identification of genotype Ib with an
amplification product of 250 bp; 4-A (59CTG CAG GCA CAC
GTG TGT 39), 4-B (59AAA AGA CGG GAA AAA AGC AA 39)
for the identification of genotype Id with an amplification product
of 200 bp (Figure 1). The amplification reactions were performed
in a total volume of 20 mL. This reaction consisted of 1X of Taq
polymerase amplification buffer (100 mM Tris-HCl, pH 8.3;
Invitrogen), 100 mM dNTPs solution, 25 mM MgCl2 solution,
5 Units/mL of Taq polymerase platinum (Invitrogen), 10 mMo f
each primer, 3 mL of DNA template and water to give a final total
volume of 20 mL. Amplification conditions were independently
established as previously reported [12]. Each reaction was carried
out in duplicate, and twenty microliters of PCR product for each
reaction were analysed by electrophoresis on a 2% agarose gel and
visualised by staining with ethidium bromide. Positive controls
were always included in the PCR assays using CG strain (TcI), VS
strain (TcII), CM17 strain (TcIII), CANIII strain (TcIV), MN cl 2
(TcV), CL Brener strain (TcVI) and 444 (T. rangeli strain).
Characterisation of presence/absence of
electrocardiographic, radiologic and echocardiogram
alterations
Seventeen cardiac abnormalities were evaluated during elec-
trocardiographic, radiologic and echocardiographic characterisa-
tion of each patient. The 17 alterations are as follows: right
bundle-branch block (1), left bundle-branch block (2), left anterior
fascicular block (3), left posterior fascicular block (4), ventricular
premature beats (5), first degree atrioventricular block (6), Mobitz
type I atrioventricular block (7), sinus bradycardia (8), primary ST-
T changes (9), abnormal Q-waves (10), low voltage QRS (11),
atrial fibrillation (12), Mobitz type II atrioventricular block (13),
complete atrioventricular block (14), complex ventricular arrhyth-
mias (15), evidence of regional wall motion abnormality (16),
reduced global left ventricular function and increased cardiotho-
racic ratio (17) [22]. Variables were taken as categorical and the
result was analysed by presence or absence of each abnormality.
The prevalence of the abnormalities was determined based on the
Figure 1. Algorithm for molecular characterization of T. cruzi DTUs based on five molecular markers.
1 Souto et al., 1996,
2 Liarte et al.,
2009,
3 Brisse et al., 2000,
4 Duffy et al., 2009 and
5 Falla et al., 2009.
doi:10.1371/journal.pntd.0000899.g001
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(p,0.05) were performed in 20 random TcI and 20 TcII patients
to find possible associations between the presence/absence of
cardiac abnormalities in patients characterised as TcI, TcII-TcIV
and possible mixed infections TcI/TcII-TcIV; also to evince
statistically significant differences in the effect of specific DTUs
with the presence/absence of cardiac abnormalities. Student t test
(p,0.05) was developed followed by a Tukey test (p,0.05) to
observe the statistically mean differences among each cardiac
abnormality and T. cruzi DTUs. Lastly, to ensure that all the
results obtained were not attributed to randomness, all the results
were randomized in PopTools 3.1.0 with 10,000 replicates
(p,0.05).
Results
T. cruzi molecular detection and characterisation
Out of 240 samples, 168 (70%) were positive by kDNA
amplification for T. cruzi DNA detection. When satellite DNA
PCR for typing T. cruzi DTUs was performed 177/240 (74%)
samples showed positive amplification, with 131/177 (74%)
patients being classified as TcI and 46/177 (26%) as TcII-TcVI
(Figure 2A). When the intergenic region of mini-exon gene was
performed, 132/240 (55%) samples were positive, 95/132 (72%)
samples corresponding to TcI and 21/132 (16%) corresponding to
TcII-TcVI; also, 16/132 (12%) samples showed both patterns of
amplifications and were considered mixed infections TcI/TcII-
TcVI. (Figure 2C). In regard to the variable domain D7 rDNA
24Sa subunit, positive amplification was observed in 161/240
samples and 136/161(71%) showed positive amplification for TcI,
25/161 (15%) showed positive amplification for TcII-TcVI.
(Figure 2B). Regarding the qPCR strategy to genotype T. cruzi,
this assay was only performed to confirm TcIII and TcIV
according to the melting temperatures previously established [25].
T. cruzi I genotypes and TcII-TcVI DTUs identification
In the single infections, TcI genotypes were detected (95/240),
and amplification results were observed for TcIa (46/95) and TcId
(8/95) genotypes. In the mixed infections, only genotype Id was
detected (16/22). Due to the low sensitivity of this molecular
marker no amplification was observed in some samples that were
positive by amplification of the intergenic region of the mini-exon
gene.
When the rDNA 18S region and 24Sa D7 domain patterns of
amplification were obtained 24/25 patients were infected with
TcII in the single infections. Regarding the results of mixed
infections obtained by Mini-exon TcI/TcII-TcVI a markedly low
frequency of TcII was observed, only 1/22 patients were infected
with TcII, 5/22 with TcIII and 10/22 with TcIV, all in mixed
infection with genotype TcId (Figure 3A–3B). The presence of
TcIII and TcIV was corroborated using the melting temperature
analysis in the qPCR assays based on the satellite DNA region
showing that those samples characterized as TcIII (5/22) and
TcIV (10/22) were ascertained those DTUs (Figure 1; Figure 3C).
Characterisation of cardiomyopathy and correlation with
molecular characterisation of the T. cruzi infection
Statistical analyses were performed in terms of trying to define
the correlation between T. cruzi genetic variability and the
presence/absence of cardiac abnormalities in chronic Chagasic
patients. The prevalence of the cardiac alterations was estimated
(Figure 4). Due to the predominance of patients infected with TcI
and the low number of patients infected with TcII, twenty random
TcI and 20 TcII samples were selected to conduct the statistical
analyses. Independence test (Chi-square p,0.05) showed associ-
ations between the presence/absence of cardiac alterations and the
infection by specific T. cruzi DTUs (p=0.037 for TcI and
p=0.039 for TcII) Student t-tests showed that there were mean
differences in the presence of cardiac alterations in patients
Figure 2. Amplification products of the DNAst, intergenic region of mini-exon gene and 24Sa rDNA region performed. Figure 2A.
Amplification product in 2% agarose gels of DNAst. Lane 1-6 Patients 111- 116 TcII-TcVI, Lane 7. Patient 87, Lane 8. 50-bp Weight Marker. Figure 2B.
Amplification product in 2% agarose gels of the D7 24Sa rDNA region. Lane 9. 100-bp Weight Marker, Lane 10. Patient 87 TcI, Lane 11. Patient 98 TcII-
TcVI, Lane 12–13. Patients 101-107 TcI. Figure 2C. Amplification product in 2% agarose gels of the intergenic regio ´n of mini-exon gene. Lane 1. 100-bp
Weight Marker, Lane 2. Patient 12 TcII-TcVI, Lane 3. Patient 34 TcII-TcVI, Lane 4–8. Patients 33-34-35-36 TcI.
doi:10.1371/journal.pntd.0000899.g002
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alterations was estimated in TcI and TcII based on the 20 samples
previously selected (Figure 4). Significant and non-significant mean
pair-wise comparison using Tukey test was developed on the 20
samples selected showing that the prevalence of most cardiac
alterations was elevated depending on TcI or TcII infection
(Figure 4). Likewise, to ensure that the results were not attributed
to randomness, all the data was randomised in PopTools 3.1.0
with 10,000 replicates and it was observed that the data were not
attributed to randomness (p=0.037). The cardiac abnormalities
were also assessed comparing the prevalence of these alterations
between the genotype TcIa and the genotype TcId, Chi-square
test based on 8 random TcIa samples and 8 TcId samples were
performed showing association between cardiac alteration and
TcIa (p=0.011) and no association between cardiac alteration and
TcId (p=0.061). Furthermore, the t-student test showed strong
Figure 3. Amplification products of the 18S, 24Sa rDNA and qPCR DNAst Tm peaks for the detection of TcIII and TcIV DTUs.
Figure 3A. Amplification products in 2% agarose gels of D7 24Sa rDNA region in T. cruzi. Lane 1. Negative control, Lane 2. Patient 54 TcIV, Lane 3.
Patient 76 TcIII, Lane 4. Patient 112 TcIII, Lane 5. Patient 212 TcII, Lane 6. Patient 12 TcII, Lane 7. Negative control, Lane 8. 50-bp Weight Marker.
Figure 3B. Amplification products in 2% agarose gels of 18S rDNA region in T. cruzi. Lane 1. Patient 57 TcIV, Lane 2. Patient 54 TcIV, Lane 3. Patient 76
TcIII, Lane 4. Patient 112 TcIII, Lane 5. Patient 212 TcII, Lane 6. Patient 12 TcII, Lane 7. Negative control, Lane 8. 50-bp Weight Marker. Figure 3C.
Melting temperature peaks of TcIII and TcIV samples by qPCR real-time.
doi:10.1371/journal.pntd.0000899.g003
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(p=0.023) demonstrating that the genotype related to the
domestic cycle of transmission presents more cardiac alterations
than those patients infected with the genotype related to the
sylvatic cycle of transmission.
Discussion
The main purpose of defining T. cruzi nomenclature must be
related with the biological, clinical and pathological characteristics
associated with specific populations of T. cruzi [14,18]. So far to
our knowledge, few correlations reported have been evidenced in
the difference of the host humoral response to specific T. cruzi
genotypes; however, these findings were flawed because of the low
reliability of the diagnostic tests used, leading to a high proportion
of false negatives due to variability in the T. cruzi strain used for the
diagnosis, the incrimination of TcI with severe forms of
myocarditis in cardiac samples from chronic chagasic patients in
Argentina and no specific clinical manifestation related to T. cruzi
DTUs in Bolivian chagasic patients show the pleomorphism of T.
cruzi [23,28,29,30]. Regarding the genetic variability of the
parasite, prognosis markers based on mitochondrial genes where
the presence of specific mutations can trigger the complications of
the chronic phase of disease in asymptomatic patients have also
been demonstrated [31,32]. Despite the genetic variability, it is
important to consider the presence of T. cruzi clones that can be
found in different tissues. Several studies have demonstrated a
specific histiotropism of T. cruzi in mice showing differences in the
pathological, immunological and clinical features the parasite can
elicit in the host [18,33,34]. Moreover, some authors have shown
that the T. cruzi population in a patient’s bloodstream could be
dissimilar to the parasite population that causes tissue damage
[35]. Differences were found in T. cruzi populations in the
bloodstreams of patients with chronic Chagasic cardiomyopathy
and of Chagasic patients without cardiomyopathy [36]. Also,
microsatellite analyses have shown multiclonality in samples of
heart and in the bloodstream of infected patients [37,38]
demonstrating that probably specific populations of T. cruzi can
determine the disease outcome.
The presence of TcIII and TcIV could possibly be explained by
the selection of T. cruzi in the amplification procedures; as
mentioned before the predominant DTU in Colombia is TcI and
Figure 4. Prevalence of electrocardiographic, radiologic and echocardiogram alterations in chronic Chagasic patients from
Colombia. (A) Prevalence of alterations based on 240 chronic Chagasic patients, (B) Prevalence of alterations based on 20 selected chronic Chagasic
patients. Right bundle-branch block (1), left bundle-branch block (2), left anterior fascicular block (3), left posterior fascicular block (4), ventricular
premature beats (5), first degree atrioventricular block (6), Mobitz type I atrioventricular block (7), sinus bradycardia (8), primary ST-T changes (9),
abnormal Q-waves (10), low voltage QRS (11), atrial fibrillation (12), Mobitz type II atrioventricular block (13), complete atrioventricular block (14),
complex ventricular arrhythmias (15), evidence of regional wall motion abnormality (16), reduced global left ventricular function and increased
cardiothoracic ratio (17). (*) Statistically significant comparisons of TcI vs. TcII cardiac alteration using Tukey test.
doi:10.1371/journal.pntd.0000899.g004
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DTU not allowing the amplification in the axenic culture of other
low parasite density DTUs. This has been evidenced in T. cruzi
isolates that are considered mixed infections especially in
congenital cases [37,39,40,41]. Another factor is that sylvatic
reservoirs might be selecting specific clones of T. cruzi. Recently,
the possible association between T. cruzi DTUs and sylvatic
reservoirs has been shown. TcI is related to opossums in the
arboreal ecotope and TcII-TcVI to armadillos in the terrestrial
ecotope where it was not possible to find opossums infected with
TcII-TcVI, suggesting the possible selection of T. cruzi DTUs in
the reservoirs [38,39,40]. Selection of T. cruzi populations could
also be caused by the factorial contact of reduviid insects in
their bloodmeal with humans and sylvatic reservoirs, such that
they can acquire different T. cruzi populations each time they feed
[14,16].
Most of the patients recruited in this study came from an
endemic region of Colombia (Santander) where wild reservoirs
and sylvatic triatomines have been reported [19,20,42]. This
diversification of sylvatic triatomines could explain the unexpect-
ed transmission of the foreseen genotypes TcIII and TcIV. Also,
the possible interaction of sylvatic triatomines in the domestic
cycle of T. cruzi transmission might be an explanation for the
appearance of TcII, TcIII and TcIV in the chronic Chagasic
patients. Infection of TcII-TcIV in Rhodnius prolixus and
Panstrongylus geniculatus has been reported and might explain the
presence of TcII-TcIV and its association with the domestic cycle
where parasites with these DTUs are infecting the patients [43].
Some hypothesis show that reservoirs from the arboreal ecotopes
such as didelphids and primates are always infected with TcI and
those associated with the terrestrial ecotopes such as armadillos
that have been found infected with TcIII and some sylvatic
rodents are infected with TcII-TcVI [44]. Recent reports show
that this distribution is not absolute because Monodelphis
brevicaudata and Philander frenata have been found infected with
TcIII and D. aurita, primates and wild non-human primates
have been infected with TcII, TcI and TcIV respectively
[45,46,47,48]. The reservoirs play an important role in the
epidemiology of Chagas disease and represent the basis of finding
patients infected with TcIII and TcIV showing rodents such as P.
semispinosus and Rattus rattus infected with TcIII or TcIV in
Colombia [49,50].
The most interesting observation is the presence of TcIII (5/
22 patients) and TcIV (10/22 patients) in the chronic Chagasic
Colombian patients. Hybridisation events have been observed in
T. cruzi based on the use of satellite DNA, rRNA sequences and
phylogenetic inferences [5,51,52,53,54]. TcIII and TcIV are
considered the Zymodeme III related to the sylvatic cycle of
transmission in the Amazon basin and also related to TcI
[55,56,57]. TcIII and TcIV are reported as a possible product of
an event of recombination between TcII and TcI. Herein, we
found the presence of genotype Id in mixed infections and the
decrease of the number of patients infected with TcII. We
recently discovered the existence of genotypes within TcI isolates
[8,9,12]. These results have been corroborated using the internal
transcribed spacer 2 (ITS-2) where three genotypes were clearly
grouped [13]. A set of 48 loci microsatellite analyses corrobo-
rated the sylvatic and domestic-peridomestic genotypes (Ia and
Id) and the recent report of the genotype TcIe supports the idea
that TcI is a really diverse DTU that requires further
investigation in order to obtain hidden information of this
DTU [7,9]. Our results demonstrate the presence of TcIV in
infected patients as previously reported in Venezuela [58]. In
addition, we report the presence of TcIV in human mixed
infection with genotype Id. Recent studies have shown the
presence of TcIa and TcId genotypes in chronic chagasic
patients from Argentina. Interestingly, the most prevalent
genotype is Ia in bloodstream and Id more prevalent in cardiac
tissue explants suggesting TcI genotype histiotropism [29]. Our
results agree with these findings when TcIa was found in 46
patients and TcId in 24 patients (8 from single infections plus 16
from mixed infections).
Statistical significance was obtained when independence tests
were performed using categorical data for the presence or
absence of cardiac alterations detected by the electrocardio-
graphic, radiologic and echocardiograpic methods. Independence
was observed when TcI and TcII were determined reflecting that
the genetic variability in T. cruzi may represent an important
factor for disease installation. Moreover, the findings of this study
demonstrate that TcI is the predominant genotype associated
with manifestations of cardiomyopathy in chronic Chagasic
patients. These results have already been confirmed where severe
myocarditis was found in patients from Argentina infected with
TcI and moderate myocarditis was caused by TcV and TcVI
despite of TcII can also cause a lower grade of severe myocarditis
[29]. The T. cruzi population distribution in the bloodstream and
in the cardiac tissue has been shown to be quite different in
previous studies [18,33,34]. Therefore, it is now really necessary
to conduct studies based on the use of cardiac tissue and
bloodstream samples to compare the T. cruzi genotypes that are
circulating in Colombian Chagasic patients and those that are
probably involved in producing organ damage in infected
patients.
In conclusion, we report for the first time the presence of TcIII
and TcIV in chronic Colombian Chagasic patients. We also
confirm the presence of TcI and TcII in chronic Chagasic
patients, and found that TcI is associated with more cardiomy-
opathy abnormalities than TcII. In addition, we describe the
predominance of TcI in Colombia and the mixed infection in the
same patient with TcI/TcII-TcIV. It is important to consider that
our study was accomplished in a restricted area and the whole T.
cruzi diversity in chronic Chagasic patients was not considered,
also the detected genotypes in bloodstream and populations that
cause organ failure may be dissimilar as has been previously
reported in Colombia: TcI in bloodstream and TcII in cardiac
tissue in a same patient [20,29,33,34]. New studies regarding most
of the endemic areas from Colombia and molecular character-
ization directly from infected organs are required to determine the
T. cruzi populations circulating in Colombian patients. New
studies are also necessary to understand the specific T. cruzi
populations that are generating the tissue damage in the infected
patients.
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